Leucovorin/levofolinate calcium

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Eli Lilly and Company

Conditions

Colon AdenocarcinomaColorectal NeoplasmsRectal Adenocarcinoma

Phase 2

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

Not yet recruitingNCT07814417

Eli Lilly and CompanyColorectal Neoplasms

Start: 2026-10-01End: 2028-11-01Target: 50Updated: 2026-09-11

Phase 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

RecruitingNCT06997497

Merck Sharp & Dohme LLCColon Adenocarcinoma, Rectal Adenocarcinoma

Start: 2025-07-16End: 2030-10-27Target: 477Updated: 2026-09-14

Related Papers

KANDLELIT-012: Phase 3 study of MK-1084 (a <i>KRAS G12C</i> inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for <i>KRAS</i> <i>G12C</i> -mutant colorectal cancer.

Journal of Clinical Oncology2026-01-10